Omeros (NASDAQ:OMER – Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.
Valuation and Earnings
This table compares Omeros and Green Thumb Industries”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Omeros | N/A | N/A | -$156.82 million | ($2.02) | -5.63 |
| Green Thumb Industries | $1.14 billion | 1.19 | $73.08 million | $0.17 | 38.35 |
Profitability
This table compares Omeros and Green Thumb Industries’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Omeros | N/A | N/A | -52.38% |
| Green Thumb Industries | 3.77% | 1.66% | 1.17% |
Risk & Volatility
Omeros has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500. Comparatively, Green Thumb Industries has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Omeros and Green Thumb Industries, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Omeros | 1 | 1 | 2 | 1 | 2.60 |
| Green Thumb Industries | 0 | 1 | 1 | 1 | 3.00 |
Omeros presently has a consensus price target of $40.33, indicating a potential upside of 254.42%. Given Omeros’ higher possible upside, equities research analysts plainly believe Omeros is more favorable than Green Thumb Industries.
Institutional and Insider Ownership
48.8% of Omeros shares are owned by institutional investors. Comparatively, 0.1% of Green Thumb Industries shares are owned by institutional investors. 12.9% of Omeros shares are owned by insiders. Comparatively, 9.4% of Green Thumb Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Green Thumb Industries beats Omeros on 8 of the 13 factors compared between the two stocks.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
About Green Thumb Industries
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
